Diana Romero on Muck Rack

Diana Romero

Verified
London, United Kingdom
As seen in: Nature, MDPI, SAGE Publishing, Taylor & Francis Online, El Espectador, Dialnet - Universidad de La Rioja, Indie Hoy, Texas Medical Center, The Cureus Journal of Medical Science, Vistazo, Impakter and
Thinking aloud about scientific and medical research while I listen to random music. Chief Editor at Nat Rev Clin Onc. Views my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Diana

Contact Diana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Teclistamab monotherapy improves survival in RRMM

|
By Diana Romero Verified
| Nature Verified
The BCMA × CD3 bispecific T cell engager teclistamab has demonstrated efficacy as monotherapy in patients with heavily pretreated relapsed and/or refractory multiple myeloma (RRMM) and, more recently, in combination with the anti-CD38 antibody daratumumab after 1–3 prior lines of therapy. However, the widespread inclusion of daratumumab in first-line regimens highlights a need to test options for patients with disease refractory to this agent and lenalidomide at first relapse.
Open in Who Shared Issue with article?

Adjuvant selpercatinib shows benefit in patients with NSCLC

|
By Diana Romero Verified
| Nature Verified
You have full access to this article via your institution. The RET tyrosine-kinase inhibitor selpercatinib is approved for the treatment of patients with advanced-stage non-small-cell lung cancer (NSCLC) harbouring RET fusions, the oncogenic driver in 1–2% of all NSCLCs. Now, results from the phase III LIBRETTO-432 trial demonstrate that selpercatinib is also efficacious in the adjuvant setting.
Open in Who Shared Issue with article?

First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2 + GEA

|
By Diana Romero Verified
| Nature Verified
Trastuzumab plus chemotherapy, with or without pembrolizumab, is the standard-of-care first-line therapy for patients with advanced-stage HER2-positive gastroesophageal adenocarcinoma (HER2+ GEA). Now, results from the global phase III HERIZON-GEA-01 trial demonstrate that chemotherapy plus the anti-HER2 biparatopic antibody zanidatamab with or without the anti-PD-1 antibody tislelizumab improves survival outcomes in this setting.
Open in Who Shared Issue with article?
See all 207 licensed articles (209 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified